Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment

被引：1

作者：

Rawson, Timothy M. ^{[1
]}

Charani, Esmita ^{[1
]}

Moore, Luke S. P. ^{[1
,2
]}

Herrero, Pau ^{[3
]}

Baik, Ji Soo ^{[4
]}

Philip, Akash ^{[3
]}

Gilchrist, Mark ^{[2
]}

Brannigan, Eimear T. ^{[2
]}

Georgiou, Pantelis ^{[3
]}

Hope, William ^{[5
]}

Holmes, Alison H. ^{[1
,2
]}

机构：

[1] Imperial Coll London, Natl Inst Hlth Res, Hlth Protect Res Unit Healthcare Assoc Infect, Hammersmith Campus,Cane Rd, London W12 0NN, England

[2] Imperial Coll Healthcare, NHS Trust, Cane Rd, London W12 0HS, England

[3] Imperial Coll London, Dept Elect & Elect Engn, South Kensington Campus, London SW7 2AZ, England

[4] Imperial Coll London, Sch Med, South Kensington Campus, London SW7 2AZ, England

[5] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3GE, Merseyside, England

来源：

JOURNAL OF INFECTION | 2017年 / 74卷 / 03期

基金：

英国工程与自然科学研究理事会; 美国国家卫生研究院;

关键词：

Vancomycin; Obesity; Antimicrobial resistance; Pharmacokinetic-pharmacodynamic; Population modelling;

D O I：

10.1016/j.jinf.2016.12.011

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：320 / 324

页数：6

共 9 条

[1] [Anonymous], 2016, Breakpoint tables for interpretation of MICs and zone diameters
[2] Antimicrobial therapy in obesity: a multicentre cross-sectional study
Charani, Esmita
Gharbi, Myriam
Frost, Gary
Drumright, Lydia
Holmes, Alison
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (10) : 2906 - 2912
[3] Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid
Craig, WA
[J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) : 479 - +
[4] Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia
Holmes, Natasha E.
Turnidge, John D.
Munckhof, Wendy J.
Robinson, J. Owen
Korman, Tony M.
O'Sullivan, Matthew V. N.
Anderson, Tara L.
Roberts, Sally A.
Warren, Sanchia J. C.
Gao, Wei
Howden, Benjamin P.
Johnson, Paul D. R.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (04) : 1654 - 1663
[5] Madady A, 2008, INT J CONTROL AUTOM, V6, P194
[6] Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?
Neely, Michael N.
Youn, Gilmer
Jones, Brenda
Jelliffe, Roger W.
Drusano, George L.
Rodvold, Keith A.
Lodise, Thomas P.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) : 309 - 316
[7] Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R
Neely, Michael N.
van Guilder, Michael G.
Yamada, Walter M.
Schumitzky, Alan
Jelliffe, Roger W.
[J]. THERAPEUTIC DRUG MONITORING, 2012, 34 (04) : 467 - 476
[8] The pharmacokinetic and pharmacodynamic properties of vancomycin
Rybak, MJ
[J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 : S35 - S39
[9] Coagulase-negative staphylococcal bloodstream infections: Does vancomycin remain appropriate empiric therapy?
Valencia-Rey, Paula
Weinberg, Janice
Miller, Nancy S.
Barlam, Tamar F.
[J]. JOURNAL OF INFECTION, 2015, 71 (01) : 53 - 60

← 1 →